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Abstract: Regeneration deficiency is one of the main obstacles limiting the effectiveness of 
tissue-engineered scaffolds. To develop scaffolds that are capable of accelerating regeneration, 
we created a heparin/chitosan nanoparticle-immobilized decellularized bovine jugular vein 
scaffold to increase the loading capacity and allow for controlled release of vascular endothelial 
growth factor (VEGF). The vascularization of the scaffold was evaluated in vitro and in vivo. 
The functional nanoparticles were prepared by physical self-assembly with a diameter of 
67–132 nm, positive charge, and a zeta potential of ∼30 mV and then the nanoparticles were 
successfully immobilized to the nanofibers of scaffolds by ethylcarbodiimide hydrochloride/
hydroxysulfosuccinimide modification. The scaffolds immobilized with heparin/chitosan 
nanoparticles exhibited highly effective localization and sustained release of VEGF for several 
weeks in vitro. This modified scaffold significantly stimulated endothelial cells’ proliferation 
in vitro. Importantly, utilization of heparin/chitosan nanoparticles to localize VEGF significantly 
increased fibroblast infiltration, extracellular matrix production, and accelerated vascularization 
in mouse subcutaneous implantation model in vivo. This study provided a novel and promising 
system for accelerated regeneration of tissue-engineering scaffolds.
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Introduction
Tissue-engineered scaffolds are the main substitute materials used to repair cardio-
vascular damage in cardiovascular diseases. However, poor integration of a tissue-
engineered scaffold into the recipient’s cardiovascular system and its incomplete 
regeneration, such as poor endothelialization and incomplete vascularization, limit 
the scaffold’s clinical effectiveness. Poor endothelialization could induce thromboge-
nicity and calcification,1 while incomplete vascularization could result in insufficient 
nutrient and oxygen supply to the scaffold.2 Conventional cardiac tissue engineer-
ing can provide oxygen diffusion only at a distance of about 150 µm due to poor 
vascularization.3,4 Therefore, complete regeneration would be a hallmark of a successful 
tissue-engineered scaffold.
We recently reported an in vivo application of decellularized scaffolds prepared 
from bovine jugular veins to reconstruct dog pulmonary and right ventricle with 
potential regeneration.5–8 This decellularized scaffold is rich in important extracellular 
matrix proteins. In combination with photo-oxidative cross-linkage, decellularized 
bovine jugular veins were able to retain tensile strength, resist thrombosis, and exhibit International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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potential for regeneration. However, the major problem is 
still the lack of cardiovascular integration and complete 
regeneration.
Regeneration of scaffolds requires formation of new blood 
vessels to supply both nutrients and oxygen.   Angiogenic 
processes are regulated by various growth factors.   Vascular 
endothelial growth factor (VEGF) is one of the most impor-
tant and widely studied growth factors, and has been shown to 
be useful for enhancing regeneration of   scaffolds.6   However, 
excessive amounts of VEGF are required because of its short 
half-life (∼50 minutes). This is usually accomplished by the 
administration of high doses of VEGF, which can induce 
severe side effects, such as undesired vascularization at 
nontarget sites, tumor growth at locations away from the 
scaffold, hypotension, and edema.9,10 In contrast, sustained 
local concentration of growth factors is necessary for the 
development of mature blood vessels. Therefore, it is particu-
larly important to localize VEGF to the scaffold and control 
its release at the site of implantation.
A number of growth factors and other bioactive molecules 
possess conserved amino acid sequences which could be the 
heparin-binding sites.11,12 Based on the specificity of fac-
tors for heparin, several heparin-containing systems have 
been developed for controlled release of growth factors.13–16 
Among these the direct immobilization of heparin onto 
the scaffold surface, and subsequent attachment of growth 
factors, is currently the most popular strategy for local 
delivery of growth factors. For instance, VEGF can be 
covalently bound to activated collagen scaffolds by cross-
linking agents.16 After attachment to heparinized acelluar 
collagen, VEGF can increase endothelial cell proliferation,17 
upregulate microvasculature formation, and stimulate blood 
vessel maturation.18–20 Polymeric matrices have also been 
successfully used to deliver angiogenic proteins to scaf-
folds and sustained release was established. These include 
dextran hydrogels,21 alginate hydrogels,22 alginate beads,23 
hyaluronan hydrogels,24 and poly(DL-lactic-co-glycolic acid 
scaffolds.25 Recently, drug delivery of VEGF via heparin-
functionalized nanoparticles/fibrin complex revealed efficient 
revascularization.10 However, there are many drawbacks 
that still hamper the clinical application of these engineered 
  scaffolds. These drawbacks include rapid release and clear-
ance of growth factors, the large dose of encapsulated pro-
teins that is required, reduced growth factor bioactivity by 
chemical modification, denaturation of the growth factor due 
to residual cross-linkers, and complications in the host caused 
by systemic administration of nanoparticles. Therefore, a 
larger loading-capacity, sustained biological activity and 
local delivery as well as controlled release of growth factors 
are the key factors for the effective application of decellular-
ized tissue-engineered scaffolds in a clinical setting.
Chitosan is a natural, biocompatible, and biodegradable 
cationic polysaccharide the applications of which in tissue 
engineering and drug delivery have been widely studied. 
The accumulated evidence demonstrated that chitosan 
could stimulate cell attachment and growth.26,27 Heparin 
is a negatively charged, linear polysaccharide present in 
many living organisms and a member of the glycosamino-
glycan   superfamily.28 The physical adsorption of heparin 
could prevent early degradation of growth factors, thereby 
preserving their biological activity. With its capacity for 
antithromobogenicity, heparin is used for suppressing acute 
subthrombus.29–31 Thus, a chitosan and heparin nanoparticle 
provides a large loading capacity while stimulating regenera-
tion and preventing early degredation.28
In this study, our main objective is to develop a scaffold 
with large loading capacity, retention of biological activity, 
and a sustained local release of VEGF to enhance the vas-
cularization of decellularized bovine jugular vein scaffolds. 
The large loading capacity was established by the applica-
tion of nanoparticles to localize VEGF. To preserve the 
biological activity, functional heparin/chitosan nanoparticles 
were prepared via physical self-assembly without residual 
cross-linkers. Local delivery and controlled release of 
VEGF was established by ethylcarbodiimide hydrochloride/
hydroxysulfosuccinimide modification of heparin/chitosan 
nanoparticles and subsequent attachment to scaffolds. This 
system exhibited a significant enhancement of regeneration 
in bovine jugular vein scaffolds.
Materials and methods
Materials
1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydro-
chloride (EDC, Sigma-Aldrich, St. Louis, MO) and 
N-hydroxysulfosuccinimide (NHS, Pierce Chemicals, 
  Dallas, TX) were used to chemically modify nano-
particles and subsequently attach them to scaffolds. 
2-(4-morpholino)ethanesulfonic acid hydrate (MES, Sigma-
Aldrich) was used as a buffer during EDC/NHS modification 
of nanoparticles and subsequent attachment to scaffolds. 
3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide 
(MTT, Sigma-Aldrich) was used for cell proliferation assay. 
Human recombinant VEGF-165 was purchased from Cell 
Signaling technology (Danvers, MA). Fluorescein diacetate 
(FDA) and Dulbecco’s Modified Eagle’s Medium (DMEM) 
were purchased from Invitrogen Inc. (Carlsbad, CA).International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Preparation of decellularized  
and photo oxidized scafffolds
The bovine jugular veins (BJV) of buffaloes (300 to 500 kg) 
were obtained from the local slaughterhouse. The scaffolds 
were prepared from BJV by multistep detergent-enzymatic 
decellularization and dye-mediated photo-oxidation proce-
dures (DP) as previously described.7 The DP scaffolds were 
the unmodified scaffolds for nanoparticle loading, modifica-
tion, and VEGF localization in this study.
Preparation of functional heparin/
chitosan nanoparticles
Low-molecular-weight chitosan was obtained by a depo-
lymerization method.32 Heparin/chitosan nanoparticles were 
prepared by physical self-assembly method. Briefly, an 
aqueous solution of chitosan (pH 5.0, 2 mL) was combined 
with aqueous heparin (5 mL) at various mass ratios and then 
magnetically stirred for 15 minutes at 30°C. The aggregates 
were removed by passing the solution through a 0.2 µm 
filter. Free heparin and chitosan were removed by washing 
the nanoparticles 3 times with distilled water and then the 
nanoparticles were collected by centrifugation at 14,000 rpm 
for 15 minutes in a bench-top centrifuge.
Particle size, distribution, and zeta potential of heparin/
chitosan nanoparticles were measured by laser diffraction 
Mastersizer (Malvern Instruments, UK). The morphology 
of nanoparticles was examined by environmental scanning 
electron microscope (SEM, JEOL, Tokyo, Japan). The 
loading efficiency and loading content of heparin in tested 
nanoparticles were determined by the amount of free hepa-
rin left in the supernatant using a colorimetric method and 
calculated as previously described.33
Loading efficiency =   (total amount of heparin added  
- free heparin)/total amount  
of heparin added × 100%.
Loading content =   (total amount of heparin added 
- free heparin)/weight of 
nanoparticles × 100%.
Immobilization of heparin/chitosan 
nanoparticles to scaffolds and then 
localizing VEGF-165
To prepare the immobilization buffer, EDC and NHS were 
dissolved in 2-(4-morpholino) ethanesulfonic acid hydrate 
(MES) buffer at a concentration of 6 mg/mL and 3.6 mg/mL, 
  respectively. The MES buffer was prepared by   dissolving MES 
in dH2O (1.06% [W/V], pH 5.5). Scaffolds (10 × 10 mm2 in area 
and 5 mm in thickness) were cut from the conduit of DP. The 
scaffolds (SF) were placed in 5 mg/mL of nanoparticle (NP) 
solution for 4 hours, and then washed with fresh phosphate 
buffer saline (PBS) for 5 × 5 minutes. The nanoparticle-treated 
scaffolds were then immersed in 1 mL of immobilization buf-
fer and continuously incubated for 4 hours at 37°C, followed 
by washing with PBS for 5 × 5 minutes to produce SF-NP 
(with EDC/NHS). The control scaffolds included: 1) unmodi-
fied scaffolds (SF-DP); 2) SF-NP incubated with PBS and 
without EDC/NHS (SF-NP no EDC/NHS).
To localize VEGF-165, scaffolds (SF-NP with EDC/
NHS, SF-NP without EDC/NHS treatments) were 
immersed in 1 mL of PBS containing 43, 113, or 237 ng/
mL of VEGF overnight at room temperature. After reac-
tion, the scaffolds were washed 5 times with fresh PBS, 
and then collected after removing free VEGF. The amount 
of VEGF remaining in the VEGF immersion solution and 
the PBS washing solution was determined by ELISA using 
the Quantikine human VEGF ELISA kit (RandD Systems). 
A standard curve ranging from 62.5 to 1000 pg/mL was 
determined by using the standard VEGF-165 protein 
provided with the ELISA kit. To quantify the physical 
adsorption of VEGF to scaffolds, 43, 113, or 237 ng/mL 
of VEGF were incubated with the SF-DP (SF-DP-VEGF) 
and free VEGF was measured.
Characteristics of SF-NP-VEGF
The scaffolds immobilized with nanoparticles and localized 
with VEGF (SF-NP-VEGF) were imaged by environmental 
scanning electron microscopy (SEM, Hitachi S-3400N, 
Japan). Surface roughness was determined by atomic force 
microscopy (AFM) (Nanoscope III, Digital Instruments, 
Santa Barbara, CA).
Quantification of VEGF release in vitro
The amount of VEGF released from SF-NP-VEGF treated with 
or without EDC/NHS (n = 3) was assessed using a commer-
cially available ELISA kit (RandD Systems). Briefly, scaffolds 
were immersed in 1 mL of release buffer (0.1% bovine serum 
albumin in PBS [pH 7.2]). The release buffer was replaced at 
designed time intervals from 0 to 30 days and frozen at -20°C 
until the analysis. Concentrations of VEGF determined from 
a standard curve ranged from 62.5 to 1000 pg/mL.
EA.hy926 cells, derived from human umbilical vein 
endothelial cells, were acquired originally from the   American 
Type Culture Collection (ATCC, Cat#: CRL-2922) and 
cultured in DMEM medium containing 10% fetal bovine 
serum. The scaffolds (SF-NP) loaded with 50 ng/mL, or International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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250 ng/mL of VEGF, were incubated in a 24-well plate for 
60 minutes before seeding cells. The SF-DP was used as a 
control. A total of 5 × 104 cells in 10 µL medium was seeded 
onto each scaffold for 1 hour at 37°C, followed by addition 
of 1 mL of fresh culture medium. Cells were continually 
cultured for 1, 3, or 7 days.
Live imaging of cell morphology  
on scaffolds
To visualize cell morphology, scaffolds seeded with 
EA.hy926 cells were imaged under confocal laser scanning 
microscopy (Leica TCS-NT) after staining with FDA. The 
seeded scaffolds were rinsed in PBS containing FDA (5 mM) 
at 37°C for 10 minutes, and finally observed under confocal 
laser scanning microscopy.
MTT assay
To determine the viability of cultured endothelial cells, 
scaffolds (SF-DP, SF-NP, SF-NP treated with 50 ng/mL or 
250 ng/mL of VEGF) were prepared as described above. 
MTT was dissolved in PBS at 5 mg/mL. Twenty microliters 
of the MTT solution was added to each well, and the plates 
were incubated at 37°C for 4 hours. After removing the 
medium, 150 µL of DMSO was added to each well. After 
gently shaking for 10 minutes, the absorbance was read at a 
wavelength of 570 nm in a plate reader.
Angiogenesis and regeneration  
potential in mice
To evaluate regeneration of scaffolds, SF-DP or SF-NP-
VEGF was implanted into the subcutaneous pockets of 
8-week-old male BALB/c mice (Chinese Academy of 
Medical Sciences). All mice were given free access to food 
and water in accordance with an approved protocol from the 
South Central University. Mice were anesthetized by intrap-
eritoneal injection of chloral hydrate. The dorsal hair coat was 
clipped, disinfected with betadine and alcohol, and a 12-mm 
dorsal midline incision was made. One subcutaneous pocket 
on each side was prepared, and 1 scaffold was inserted into 
each pocket. The incision was then closed with interrupted 
prolene sutures. Each mouse received 2 implants of the same 
composition, and 6 mice were assigned to each group. Four 
and 8 weeks post surgery, the mice were sacrificed and tissue 
sections were prepared from the implants.
Histological characteristics
Formalin-fixed, paraffin-embedded sections were stained 
with hematoxylin and eosin (H&E) to evaluate cell   infiltration 
and capillary density. The capillaries were counted under 
light microscopy. The density of capillary per mm2 was 
calculated by the total amount of capillaries in 10 random 
areas of 1 mm2/10. The endothelial cells were further identi-
fied by anti-CD31 antibody (Bioss Biological Technology 
Ltd., China). The primary myelofibrosis was detected by 
Herovici staining.34 Scott’s alcian blue method was used to 
detect glycosaminoglycans.35 Macrophages were detected 
by CD68 antibody (clone MAC 387, Lab Vision Corp.) as 
previously described.36 Fibroblasts were characterized by the 
presence of vimentin antigen and stained with polyclonal 
rabbit antibody (Bioss Biological Technology Ltd., China) 
by following the established protocol.37
Briefly, the postoperative scaffolds were fixed with 10% 
formalin overnight at 4°C. After they were washed with PBS, 
the scaffolds were embedded in paraffin and cut into 5-µm 
sections. After deparaffinization and rehydration, the scaffold 
sections underwent antigen retrieval with citric acid solu-
tion (Maixin Biological Technology Ltd, CA) in a pressure 
cooker for 3 minutes. The sections were then incubated with 
peroxidase inhibitor (3% H2O2) in the dark for 15 minutes, 
and nonspecific sites were blocked by 10% goat serum for 
30 minutes at room temperature. Sections were then incubated 
with primary antibody for 1 hour at room temperature. Slides 
were washed twice with PBS, and secondary antibody (Super 
Sensitive Detection System; Maixin) was then applied. After 
slides were washed with PBS again, they were developed 
with diaminobenzidine Chromogen (Maixin) for 15 minutes. 
Slides were washed with water, counterstained with Gill’s 
hematoxylin and placed in 0.5% ammonium hydroxide.
Statistical analysis
The experimental values are expressed as mean ± SEM. 
Comparisons between the two groups were performed with 
a 2-tailed t test for unpaired data. A P , 0.05 was considered 
to be statistically significant.
Results
Characteristics of heparin/chitosan 
nanoparticles
Table 1 shows the particle size, polydispersity (PDI), and zeta 
potential of nanoparticles which were prepared at various 
concentrations of chitosan and heparin with a ratio of 5:2 in 
mass (pH 4.5). Table 2 shows the particle size, PDI, and zeta 
potential of nanoparticles which were prepared at pH 4 to 6 
of chitosan (1 mg/mL) and heparin (2 mg/mL). The particle 
size of the nanoparticles varied from 67 to 132 nm and their 
zeta potential values were positive or negative.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Pores 450 nm in diameter and fibers 1.2 µm diameter were 
also observed (Figure 1A and B). The SF-NP exhibited 
sheaths enclosed within a bundle of nanofibers (Figure 1C 
and D). Surface roughness was determined by AFM. As 
shown in Figure 1E and F, the SF-NP has a smoother sur-
face (RMS = 67.34 nm), while SF-DP had a rougher surface 
(RMS = 137.83 nm) (Figure 1E and F).
Scaffolds immobilized with nanoparticles 
loaded more VEGF
VEGF could be localized to nanoparticles abundantly and 
stably through physical adsorption and modification of 
scaffolds. As shown in Figure 2A, VEGF was loaded in a 
concentration-dependent manner. The SF-NPs with EDC/
NHS treatment exhibited significantly greater efficiency 
(P , 0.01) in loading VEGF compared with SF-NP without 
EDC/NHS treatment and SF-DP at graded concentrations of 
VEGF (Figure 2A). Interestingly, SF-DP loaded 43 ± 8 ng of 
VEGF, possibly because the chondroitin sulfate in extracel-
lular matrix was able to attach to VEGF.
Controlled release of VEGF
The release of VEGF from nanoparticles immobilized to 
scaffolds was analyzed over a period of 30 days (Figure 2B). 
VEGF was released with a high burst (62% to 70%) dur-
ing the first 3 days and 86% to 93% of the total VEGF 
was released at 7 days from SF-NP-VEGF without EDC 
modification (physical adsorption). In contrast, VEGF was 
released with a significantly reduced burst from SF-NP-
VEGF with EDC modification (physical adsorption plus EDC 
modification). The lower concentration group (50 ng/mL) 
released ∼37.12% at 30 days and the higher concentra-
tion group (250 ng/mL) released 42.17% at 30 days. In the 
EDC-modified SF-NP-VEGF, VEGF localized by massive 
nanoparticles still existed on the surface of scaffolds while 
some nanoparticles had swelled to a large diameter at 4 and 
10 weeks (Figure 2C and D).
Effect of nanoparticle-localized VEGF  
on endothelial cell proliferation in vitro
To test whether our SF-NP-VEGF could promote vascu-
larization in decellularized scaffolds, we performed MTT 
assay to measure the viability and proliferation of endothelial 
cells on scaffolds. As shown in Figure 3A, SF-NP-VEGF, 
loaded with 50 ng/mL or 250 ng/mL of VEGF induced clear 
increases in the proliferation of endothelial cells at day 3 
and day 7 compared with SF-DP. This result suggests that 
VEGF localized by nanoparticles promoted the endothelial 
Table 1 The effect of concentration on the characteristics of 
Heparin/Chitosan nanoparticles
Heparin  
conc 
(mg/mL)
Chitosan  
conc 
(mg/mL)
Particle  
size 
(nm)
Polydispersity  Zeta  
potential 
(mv)
0.5 1 72.1 ± 7.3 0.117 ± 0.008   28.5 ± 1.2
1 2 87.6 ± 6.2 0.157 ± 0.011   29.2 ± 1.7
1.5 3 98.8 ± 8.7 0.192 ± 0.013   30.1 ± 1.5
3 1.5 83.6 ± 2.3 0.087 ± 0.005 -14.6 ± 3.9
2 1 79.2 ± 6.1 0.056 ± 0.003 -19.1 ± 2.1
1 0.5 70.1 ± 5.7 0.135 ± 0.068 -23.8 ± 5.1
Notes: heparin/chitosan = 2/5; n = 4.
Table 2 The effect of pH value on the characteristics of Heparin/
Chitosan nanoparticles
Heparin 
pH
Particle size 
(nm)
Polydispersity  Zeta potential 
(mV)
4   68.3 ± 3.4 0.090 ± 0.018 26.1 ± 2.6
4.5   75.1 ± 3.1 0.135 ± 0.068 27.1 ± 1.1
5 103.0 ± 6.2 0.176 ± 0.074 29.1 ± 1.7
5.5 238.2 ± 12.3 0.290 ± 0.087 29.4 ± 0.8
6 876.6 ± 52.8 0.610 ± 0.110 29.2 ± 3.1
Notes: Heparin = 1 mg/mL; Chitosan = 2 mg/mL; n = 4.
The PDI measures the homogeneity with ranges from 
0 to 1. A higher PDI indicates a higher heterogeneity. In this 
study, nanoparticles were chosen with positive charge, about 
30 mV zeta potential, and a PDI of 0.086 ± 0.007.
We found that the loading efficiency of nanoparticles 
prepared by 2 mg/mL of chitosan with 1 mg/mL of heparin 
or 1 mg/mL of chitosan with 0.5 mg/mL of heparin with 
a 4:1 mass ratio (chitosan:heparin) was highest and no 
differences were observed between the two preparations 
(93.2% ± 1.43%, P . 0.05). However, the loading content 
of nanoparticles prepared at 2 mg/mL of chitosan with 
1 mg/mL of heparin (0.68 ± 0.17 mg/mg) was greater than 
that of nanoparticles prepared at 1 mg/mL of chitosan with 
0.5 mg/mL of heparin (0.43 ± 0.06 mg/mg). Therefore, the 
nanoparticles prepared with the former formulation were 
chosen for the subsequent studies.
Porous structure of scaffolds  
with immobilized nanoparticles  
and localized VEGF
The morphology of scaffolds was observed under environ-
mental SEM. The SF-DP exhibited nanofiber character-
istics, such as 3-dimensional structure, high porosity, and 
high surface-to-volume ratio. The microporous structure of 
SF-DP consisted of interconnected pores with an average 
diameter of 120 nm and an average wall thickness of 230 nm. International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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cell proliferation on the surface of scaffolds. To minimize 
the influence of affinity for different scaffolds, we performed 
MTT assay 8 hours after cell seeding and found no signifi-
cant differences between SF-NP-VEGF (50 or 250 ng/mL 
of VEGF) and SF-DP (data not shown).
We further observed the morphological changes of 
endothelial cells. As expected, SF-NP-VEGF exhibited more 
elongated endothelial cells on the surface of scaffolds at 
day 3 and day 7 of the incubation compared with unmodified 
  scaffolds (SF-DP). Importantly, FDA staining showed signifi-
cantly more circular structures in endothelial cells in the SF-
NP-VEGF group compared with the SF-DP group (Figure 3B). 
These circular structures might suggest cell organization and 
vascularization, rather than cell aggregation alone.
Histological evidence of regeneration
Regeneration of scaffolds was further analyzed by subcuta-
neous implantation of EDC-modified SF-NP-VEGF scaf-
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Figure 1 The morphology of scaffolds. A) Morphology of photo-oxidative cross-linked decellularized scaffolds (SF-DP) from bovine jugular vein (BJV), magnification × 10,000. 
B)  Morphology  of  SF-DP,  magnification  ×  30,000.  C)  Morphology  of  heparin/chitosan  (HEP/CS)  nanoparticle-immobilized  scaffold  (SF-NP),  magnification  ×  10,000. 
D) Morphology of HEP/CS nanoparticle-immobilized scaffold (SF-NP), magnification × 30,000. E) Surface roughness of SF-DP determined by atomic force microscopy (AFM). 
F) Surface roughness of SF-NP determined by AFM.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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folds in mice. Encouragingly, new vessels were easily seen 
in   SF-NP-VEGF scaffolds at 4 weeks and 8 weeks after 
implantation while fewer new vessels were seen in SF-DP 
scaffolds (Figure 4). H&E staining also showed new capillaries 
in repopulated layers and tissues surrounding the implanted 
SF-NP-VEGF scaffolds, whereas almost no noticeable capil-
laries were observed in SF-DP scaffolds at 4 weeks. Eight 
weeks after implantation, SF-NP-VEGF scaffolds showed 
significantly more new capillaries than SF-DP (Figure 5A). 
The difference in capillary density (the number of capillaries 
per mm2) between SF-NP-VEGF (132 ± 26 for 250 ng/mL 
VEGF, 118 ± 19 for 50 ng/mL VEGF) and SF-DP (39 ± 8) 
was statistically significant (P , 0.001, n = 8) (Figure 5B). The 
significant vascularization in the SF-NP-VEGF implantation 
was further verified by CD31staining (Figure 6). Thus, the 
angiogenic bioactivity of nanoparticle-localized VEGF was 
evident in vivo.
The migration of host cells into the scaffolds was analyzed 
by the infiltration of host cells into scaffolds. In the SF-NP-
VEGF (250 ng/mL) implant, host cells were homogenously 
distributed into one-fourth of the outer surface of scaffolds 
at 4 weeks and three-fourths at 8 weeks (Figure 5). This 
suggests that the migration process began at the adventitia 
and proceeded continuously towards the luminal surface. In 
the SF-DP implant, distribution of host cells was observed 
at only one-tenth of the outer surface of scaffolds at 4 weeks 
and one-fourth at 8 weeks.
Generally, surface collagen cross-linkage could 
reduce immunological response, but it also blocks cellular 
  infiltration. We further verified that the main infiltrated cells 
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were fibroblasts (the vimentin positive cells) (Figure 7) and 
only a few macrophages (Figure 8) were seen at 8 weeks 
post implantation.
Figure 9 shows staining for extracellular matrix com-
ponents of scaffolds at 4 and 8 weeks post implantation. 
Herovici staining showed the red mature collagen fibrils 
in all layers, but SF-NP-VEGF showed more new collagen 
fibrils (blue) (Figure 9B and C). Scott’s alcian blue staining 
showed that glycosaminoglycans were present in all layers of 
the wall (Figure 10). In the SF-NP-VEGF implant, blue newly International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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to the decellularized BJV scaffolds. The nanoparticle-
immobilized scaffolds exhibited a high loading capacity and 
controlled release for VEGF which enhanced vascularization 
of the scaffold in vitro and in vivo.
In this study we prepared heparin/chitosan nanopar-
ticles by self-assembly. Interestingly, their zeta potential 
values were either positive or negative. The positive or 
negative charges might be determined by the relative ratios 
of the surface molecules (chitosan or heparin), which-
ever is more dominant (Table 1). Most heparin/chitosan 
nanoparticles exhibited positive charges because they 
were covered with more chitosan than heparin. However, 
we hypothesized that nanoparticles with higher ratios of 
heparin to chitosan on the surface will exhibit a nega-
SF-DP, 8-week
SF-DP, 4-week SF-NP-VEGF, 4-week
SF-NP-VEGF, 8-week
Figure 4 New vessel formation in SF-NP-VEGF implants. More new vessels were 
clearly seen in SF-NP-VEGF scaffolds at 4 weeks and 8 weeks after implantation.
Abbreviations: DP, decellularized scaffolds; NP, nanoparticle; SF, scaffolds; VEGF, 
vascular endothelial growth factor
0
4-week 8-week
20
40
60
80
100
120
140
160
Scaffolds
C
a
p
i
l
l
a
r
y
 
n
u
m
b
e
r
s
 
p
e
r
 
m
m
2
SF-DP
SF-NP-VEGF (50 ng, NO EDC)
SF-NP-VEGF (50 ng)
SF-NP-VEGF (250 ng)
B
A
SF-DP, 4-week SF-NP-VEGF, 4-week
SF-DP, 8-week SF-NP-VEGF, 8-week
Figure 5 H&E staining of implant sections and capillary density. A) H&E staining 
showed new capillaries in repopulated layer and tissues surrounding the implants at 
4 and 8 weeks, original magnification × 200. B) The capillary density calculated as 
the number of capillaries per mm2. 
Notes: N = 8; P , 0.001.
Abbreviations:  H&E,  hematoxylin  and  eosin;  DP,  decellularized  scaffolds;  NP, 
nanoparticle; SF, scaffolds; VEGF, vascular endothelial growth factor
synthesized collagen fibrils were produced by fibroblasts 
and covered one-sixth of regions near the outer layer at 4 
weeks. The glycosaminoglycans were present in the outer 
layer regions in accordance with newly synthesized collagen 
fibrils, as well as the areas of the host cell repopulation. At 
8 weeks, the newly synthesized collagen fibrils (Figure 9) 
and glycosaminoglycans (Figure 10) were distributed on 
half of the walls of the scaffold. In the SF-DP group, newly 
synthesized collagen fibrils and glycosaminoglycans covered 
less than one-fourth of the surface area. This suggests that 
SF-NP-VEGF could accelerate cell infiltration and tissue 
remolding.
Discussion
Optimal tissue-engineered cardiovascular structures should 
be fully biocompatibile and capable of complete   regeneration. 
In our previous study, decellularized BJV scaffolds were used 
to reconstruct sections of pulmonary arteries and right ven-
tricles in a dog. This invention provided a preliminary view 
that the acellular BJV scaffolds could resist thrombosis and 
calcification with good regeneration potential and excellent 
hemodynamic performance.5–8 In spite of the progress with 
this scaffold, there are still some issues, such as the delayed 
regeneration and insufficient revascularization, which still 
needed to be resolved. In this study we created a heparin/
chitosan nanoparticle, which can be effectively immobilized International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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SF-DP, 4-week SF-NP-VEGF, 4-week
SF-DP, 8-week SF-NP-VEGF, 8-week
Figure 6 CD31staining of implant sections. The endothelial cells were stained by 
anti-CD31 antibody, original magnification × 200. 
Note: The arrows indicate the positive staining.
Abbreviations: CD31, cluster of differentiation molecule 31; DP, decellularized 
scaffolds; NP, nanoparticle; SF, scaffolds; VEGF, vascular endothelial growth factor
SF-DP, 8-week SF-NP-VEGF, 8-week
SF-DP, 4-week SF-NP-VEGF, 4-week
Figure 7 Immunohistochemical staining of fibroblasts. The fibroblasts were stained 
by anti-vimentin antibody, original magnification × 200. The red stained cells are the 
fibroblasts. 
Note: The arrows indicate positive staining.
Abbreviations: DP, decellularized scaffolds; NP, nanoparticle; SF, scaffolds; VEGF, 
vascular endothelial growth factor
SF-DP, 8-week SF-NP-VEGF, 8-week
SF-DP, 4-week SF-NP-VEGF, 4-week
Figure 8 Immunohistochemical staining of macrophages. The macrophages were 
stained by anti-CD68 antibody, original magnification × 100. 
Note: The arrows indicated red staining cells are macrophages.
Abbreviations: CD68, cluster of differentiation molecule 68; DP, decellularized 
scaffolds; NP, nanoparticle; SF, scaffolds; VEGF, vascular endothelial growth factor
SF-DP, 8-week
SF-DP, 4-week SF-NP-VEGF, 4-week
SF-NP-VEGF, 8-week
Figure 9 Herovici staining of collagen fibrils. Staining showed extracellular matrix 
components of scaffolds at 4 and 8 weeks implantation, original magnification × 200.
Notes: Red indicates the mature collagen fibrils and blue indicates new collagen 
fibrils. The arrows indicate positive staining of new collagen fibrils. 
Abbreviations: DP, decellularized scaffolds; NP, nanoparticle; SF, scaffolds; VEGF, 
vascular endothelial growth factor
in immobilizing to the surface of scaffolds and localizing 
VEGF. This might be because the main components of 
the decellularized tissue-engineered scaffolds are collagen 
fibers, which are negatively charged under physiological 
conditions. Thus, nanoparticles with positive charges can 
effectively bind to the scaffolds. We also found that the 
tive charge and could bind more VEGF. Unexpectedly, 
the primary experiment revealed that nanoparticles with 
negative charges were unevenly distributed throughout 
the surface of the scaffolds. In contrast, nanoparticles 
with positive charge and a zeta potential of ∼30 mV and 
a relatively uniform size ,0.10 (PDI) were more efficient International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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bind heparin with the greatest affinity. However, VEGF-169 
and VEGF-206 can diffuse into the extracellular matrix and 
affect the cellular uptake due to their excessive affinity. In 
contrast, VEGF-165 is a better candidate for the study of 
controlled local release because of relatively lower affinity 
and effective revascularization. Importantly, after the hepa-
rin/chitosan nanoparticles were immobilized to the natural 
nanofiber of scaffolds, they were able to load   significantly 
more VEGF-169 (Figure 2a). We hypothesized that during 
the cross-linking procedure, electrovalent bonds turned into 
covalent bonds, which not only produces zero-length amide 
cross-linkages between the amido groups of nanoparticles 
and carboxyl groups of scaffolds, but also mediated the reac-
tion between carboxyl groups of nanoparticles and amido 
groups of VEGF. This structure might confer to heparin/
chitosan nanoparticles the capability to load more VEGF.
Currently, local delivery of angiogenic growth factors 
is the primary strategy used to promote vascularization 
within scaffolds. The established approaches include the 
encapsulation of growth factors in scaffolds and immo-
bilization of growth factors to the surface of scaffolds by 
direct chemical cross-link.16 These strategies could main-
tain a steady supplement of growth factors locally due to 
a delayed release from the decellularized scaffolds, which 
effectively induces angiogenesis within the engineered 
  tissues. However, the drawbacks of the denaturation of 
growth factors due to residual cross-linkers, and compli-
cations in the host caused by systemic administration of 
nanoparticles, still hampered the clinical application of 
these engineered scaffolds. A significant advantage of our 
delivery system is that the nanoparticles and EDC modi-
fication mediated local delivery and controlled release of 
VEGF. In addition, with EDC modification, the initial burst 
of VEGF released was significantly reduced, which not 
only extended VEGF clearance time, but also reduced the 
toxicity of VEGF due to rapid release. The release pattern 
observed in this study suggests that 3 possible populations 
of VEGF-molecules might exist. The first population is the 
VEGF that was adsorbed to scaffolds and glycosaminogly-
cans, a component of extracellular matrix. This includes a 
nonspecific adsorption through electrostatic adherence and 
hydrophobic effects depending on the extracellular matrix 
in scaffolds. Although the physical adsorption of growth 
factors on the surface of scaffolds could also be achieved 
by heparin and fibronectin modification on the collagen 
scaffold and could effectively promote cell proliferation 
in vitro, it is less efficient in vivo.40 The second population 
might be the major population. In this population, VEGF 
was sequence-specifically bound to heparin. The third 
SF-DP, 8-week SF-NP-VEGF, 8-week
SF-DP, 4-week SF-NP-VEGF, 4-week
Figure 10 Glycosaminoglycans (GAG) staining. Scott’s alcian blue staining showed that 
GAGs were present in all layers of the wall, original magnification × 100. More blue 
staining (new collagen fibrils) was observed in SF-NP-VEGF implant at 4 and 8 week.
Note: The arrows indicate positive staining of new collagen fibrils.
Abbreviations: DP, decellularized scaffolds; NP, nanoparticle; SF, scaffolds; VEGF, 
vascular endothelial growth factor
loading efficiency of nanoparticles exhibited no signifi-
cant difference between   different preparations, possibly 
because the amount of chitosan used (positive charge) 
significantly exceeded the amount of heparin (negative 
charge). Therefore, almost all of heparin molecules were 
cross-linked with chitosan into the complexes and yielded 
a high loading efficiency. The optimal size of nanoparticles 
designed for drug delivery is approximately 50 to 150 nm, 
which confers a high surface area-to-volume ratio. In this 
study, the particle size of the heparin/chitosan nanopar-
ticles varied from 67 to 132 nm, suggesting an ideal size 
for drug delivery.
The heparin/chitosan nanoparticles were immobilized 
to the natural nanofiber of scaffolds through chemical 
  modification. The microporous structure of scaffolds con-
sisted of interconnected pores with an average diameter of 
120 nm (Figure 1). Therefore, nanoparticles (67 to 132 nm 
in size) could not only cover the surface of scaffolds, but 
also penetrate deep into the matrix through interspaces. This 
is why a smoother surface was observed in nanoparticle-
bound scaffolds (SF-NP) (Figure 1). Previous studies 
demonstrated that EDC can reinforce the nanoparticle’s 
structure.38,39 Therefore, chemical modification might also 
make the scaffold smooth and tight, which should be suit-
able for the endothelial cell attachment and proliferation. 
Among the big family of vascular endothelial growth fac-
tors, isoforms 165, 169, and 206 (VEGF-165, -169, -206) International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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population is the VEGF covalently bonded to heparin by 
EDC modification. We proposed that EDC modification 
contributed to the controlled release of VEGF. In contrast, 
without EDC modification, most VEGF was immobilized 
to SF-NP via electrovalent bond to chondroitin sulfate, the 
main constituents of glycosaminoglycans.
The recruitment of functional cells such as endothe-
lial and fibroblast cells plays a vital role in regeneration, 
while the extracellular matrix could sustain the growth and 
reproduction of the cells. Our in vitro study demonstrated 
that nanoparticle-localized VEGF led to endothelial cell 
proliferation in the scaffolds (Figure 3). Our in vivo study 
clearly demonstrated that massive new capillary formation 
(Figures 4, 5, and 6) was observed in the implanted scaffolds 
immobilized with nanoparticle-localized VEGF. However, a 
significant problem with VEGF alone is that it induces the 
formation of atypical blood vessels. These large, leaky ves-
sels are not fully functional. Therefore, the addition of other 
stabilizing factors is necessary to induce the formation of 
more functional vessels. Importantly, implantation of scaf-
folds with nanoparticle-localized VEGF not only enhanced 
large vessel growth (Figure 4), but most of the vessels are 
small capillaries (Figures 5 and 6). The significant role of SF-
NP-VEGF might be associated with either the localization 
of VEGF to the scaffold or the biological activity of heparin, 
because VEGF usually has diffusion limitations and fails 
to be actively taken up by cells residing on the peripheral 
surfaces of the scaffold. In addition, heparin could prevent 
early degradation of growth factors, while chitosan could 
stimulate cell attachment and growth.26,28 Moreover, heparin 
is an effective anticoagulant used during vascular injury.41
We also observed massive cellular infiltration in the SF-
NP-VEGF implants (Figure 5). The infiltrating cells were 
further verified to be mainly fibroblasts (Figure 7). This fibro-
blast infiltration was accompanied by significant synthesis 
of new collagen fibers (Figure 9) and glycosaminoglycans 
(Figure 10). Fibroblasts may synthesize collagen and other 
extracellular matrix proteins for further tissue remolding. 
This provided solid evidence for regeneration. Another sig-
nificant advantage is that our system is highly biocompatible 
and biodegradable. For instance, the acellular scaffolds could 
provide plenty of highly homologous extracellular matrices to 
humans. Chitosan is a natural biocompatible and biodegrad-
able cationic polysaccharide.26 Heparin is a natural, linear 
polysaccharide present in many living organisms.28 With 
physical self-assembly, the chitosan/heparin nanoparticles 
retained biological activities. Also, the whole system is 
composed of biomaterials without any artificial or synthetic 
materials. The highly biocompatible characteristic of the 
nanoparticles was shown by the limited macrophage repopu-
lation observed in the early implantation stage   (Figure 8). 
Macrophages are important contributors to biological scaf-
fold degradation and early remodeling events.
Most current strategies for revascularization of scaffolds 
utilize growth factors to attract and localize vascular endothelial 
cells, such as the strategy described in this study. Most recently, 
a study with endothelial progenitor cells (EPC) demonstrated 
that EPC cultured in contact with heparinized matrices loaded 
with VEGF revealed the highest rate of cell proliferation.42 
Implantation of scaffolds seeded with VEGF-expressing stem 
cells led to a 2- to 4-fold increase in vessel density 8 weeks 
after implantation.43 Attracting and localizing EPC could be 
a novel strategy for endothelialization because EPCs are the 
type of predifferentiated stem cells that have the potential to 
proliferate and differentiate into mature endothelial cells. Also, 
EPCs exhibited an excellent ability to enhance the function 
of ischemic organs by stimulating the re-endothelialization 
of injured blood vessels and by inducing and modulating vas-
culogenesis and angiogenesis in areas with reduced oxygen 
supply.44,45 However, peripheral blood of healthy adults contains 
very low concentrations of EPCs. With our decellularized 
tissue-engineered scaffolds immobilized with nanoparticles 
localizing high loading of VEGF, EPCs might be effectively 
attracted and then endothelialized in vivo.
Conclusions
Besides the major finding that a controlled release of VEGF 
can enhance regeneration of decellularized BJV scaffolds, 
this system provided excellent biocompatibility. The func-
tional heparin/chitosan nanoparticles exhibit high loading 
capacities, while EDC modification can mediate a controlled 
release of VEGF locally. Our results support heparin/
chitosan nanoparticle as a functional drug delivery agent 
to localize VEGF onto scaffolds and keep its bioactivity 
stable for weeks. With accelerated regeneration and excel-
lent biocompatibility, our system exhibited good therapeutic 
potential. Further studies with a longer follow-up period, a 
combination of multiple growth factors, and reconstruction of 
connections between pulmonary arteries and right ventricles 
of large animals should be conducted before this system can 
be applied in the clinic.
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